Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).

Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study). - Fpllow-up study of multicenter, prospective, randomised and comparative study of alternative anti-androgen (AA) therapy and early initiating enzalutamide for castration-resistant prostate cancer (CRPC) after combined androgen blockade (CAB) therapy with bicalutamide (OCUU-CRPC follow-up study).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039155

Enrollment

103

Registered

2020-01-21

Start date

2019-02-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Castration-resistant prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Of the 103 patients who obtained consent in the OCUU-CRPC study and were assigned at each institution.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
overall survival (OS)	—

Secondary

Measure	Time frame
time to treatment failure of ENZA therapy (TTF-ENZA)	—

Countries

Japan

Contacts

Public ContactTaro Iguchi

Osaka City University Graduate School of Medicine Department of Urology

taro@msic.med.osaka-cu.ac.jp06-6645-3857

Outcome results